✦ LIBER ✦

[497] TWO-YEAR RESULTS OF A PHASE III COMPARATIVE TRIAL OF TELBIVUDINE VS LAMIVUDINE IN CHINESE PATIENTS

✍ Scribed by J.-D. Jia; J.-L. Hou; Y.-K. Yin; D.-Z. Xu; D. Tan; J. Niu; X.-Q. Zhou; Y. Wang; L. Zhu; N. Brown

Book ID: 117375591
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 144 KB
Volume: 46
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(07)62095-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Two-year results of a randomized, phase

Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients

✍ Jia, Ji-Dong; Hou, Jin-Lin; Yin, You-Kuan; Tan, De-Ming; Xu, Daozhen; Niu, Jun-Q 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 390 KB

219 Results of a one-year international

219 Results of a one-year international phase IIB comparative trial of telbivudine, lamivudine, and the combination, in patients with chronic hepatitis B

✍ Ching-Lung Lai; Nancy W.Y. Leung; Eng-Kiong Teo; Florence Wong; Hie-Wan Hann; St 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

Telbivudine versus lamivudine in Chinese

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial

✍ Jinlin Hou; You-Kuan Yin; Daozhen Xu; Deming Tan; Junqi Niu; Xiaqiu Zhou; Yuming 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB

Chronic hepatitis B and its life-threatening sequelae are highly prevalent in China. There is a need for effective new therapies to suppress hepatitis B virus (HBV) replication and ameliorate liver disease. In this study, we compared the efficacy of telbivudine, a nucleoside analogue, with lamivudin

493 Phase III comparison of telbivudine

493 Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year

✍ E. Gane; C.L. Lai; Y.E. Liaw; S. Thongsawat; Y. Wang; Y. Cheng; J. Heathcote; J. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 244 KB

Population (POP) Pharmacokinetics (PK) o

Population (POP) Pharmacokinetics (PK) of Lamivudine (3TC) in HIV Infected Patients: Results from Two Phase III Clinical Trials

✍ Yuen, G.J.; Benoit, S.; Rubin, M. 📂 Article 📅 1996 🏛 Nature Publishing Group 🌐 English ⚖ 156 KB

42 Results of a one-year international p

42 Results of a one-year international phase IIB trial of LDT, and LDT plus lamivudine, in patients with chronic hepatitis B

✍ S.H. Han; N.W.Y. Leung; E.K. Teo; M. Tong; F. Wong; H.W. Hann; T. Poynard; N.A. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 61 KB